Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 known ✓ | P08238 | 1/20 | 0.35 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.34 |
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.33 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985163 | 0.98 | ALDH1A1 (0.38) | ALDH1A1GPR55HSP90AA1HSP90AB1POLB | |
| Hydrochloric Acid SCHEMBL5249550 | 0.95 | ALDH1A1 (0.36) | ALDH1A1GPR55HSP90AA1HSP90AB1POLB | |
| Hydrochloric Acid SCHEMBL5754089 | 0.84 | NR1I2 (0.33) | ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL5759783 | 0.82 | NR1I2 (0.33) | ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL5756540 | 0.81 | ALDH1A1 (0.35) | ALDH1A1POLBMAPTGAAKMT2A | |
| SCHEMBL5761337 | 0.81 | ALDH1A1 (0.35) | ALDH1A1POLBMAPTGAAKMT2A | |
| SCHEMBL5759411 | 0.78 | ADRB2 (0.43) | ALDH1A1HSP90AA1HSP90AB1 | |
| SCHEMBL5755967 | 0.72 | PIK3CA (0.42) | ALDH1A1HSP90AA1HSP90AB1POLBPIK3CD | |
| Hydrochloric Acid SCHEMBL5753022 | 0.68 | L3MBTL1 (0.40) | ALDH1A1HSP90AA1HSP90AB1PIK3CDPIK3CA | |
| SCHEMBL16040071 | 0.66 | MAPT (0.49) | ALDH1A1POLBPIK3CAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1108712-B1 | 3-Hydroxy-4,5-bis(morpholin-1-yl)pyridazine as UV absorber | SHISEIDO CO LTD (JP) | 2007-04-11 | — | — | EP | disclosed |
| CN-1147478-C | Pyridazine derivative and its preparation and composite containing the derivative | ������������ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| US-6476024-B1 | Pyridazine derivatives and related composition | SHISEIDO CO. LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-6395896-B2 | REACTING AT LEAST 10 WT % OF 4,5-DICHLORO-3-HYDROXYPYRIDAZINE OR 4,5-DIBROMO-3-HYDROXYPYRIDAZINE OR A MIXTURE WITH ATLEAST 20 VOL% OF MORPHOLINE IN A REACTION SOLUTION AT 70 DEGREE C. OR HIGHER; ULTRAVIOLET ABSORBENTS AND PHOTOSTABILIZERS | SHISEIDO CO., LTD. (JP) | 2002-05-28 | — | — | US | disclosed |
| CN-1308068-A | Pyridazine derivative and its preparation and composite containing the derivative | SHISEI CO LTD (JP) | 2001-08-15 | — | — | CN | disclosed |
| US-20010012841-A1 | Pyridazine derivatives, manufacturing method and related composition | SHISEIDO CO., LTD. (JP) | 2001-08-09 | — | — | US | disclosed |
| EP-1108712-A1 | 3-Hydroxy-4,5-bis(morpholin-1-yl)pyridazine as UV absorber | SHISEIDO COMPANY LIMITED (JP) | 2001-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012841-A1 | Pyridazine derivatives, manufacturing method and related composition | CYP4F12, CYP4Z1, CYP3A5 | HSP90AA1 3225/4885HSP90AB1 3185/4885PIK3CD 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.